NEW YORK, February 24, 2025--(BUSINESS WIRE)--OS Therapies, Inc. (NYSE-A: OSTX), a clinical-stage biotechnology company advancing immunotherapies and targeted drug conjugates for cancer treatment, ...
NEW HAVEN, Conn., March 04, 2025 (GLOBE NEWSWIRE) -- Cybrexa Therapeutics, a clinical-stage oncology biotechnology company developing a novel class of tumor-targeting peptide-drug conjugate (PDC) ...
Cancer treatments often struggle with balancing efficacy and side effects. A new study scientists offers a promising solution using antibody-peptide inhibitor conjugates to target specific cell types ...
Biopharmaceutics is a rapidly growing research field that aims at producing viable therapeutic and prophylactic treatments for many diseases. The use of biological therapies has increased ...
Manufacturing of antibody drug conjugates requires high-containment solutions, such as high-performance aseptic isolators. Isolators have been used successfully for many years for product protection ...
Genitourinary oncologist Jonathan Rosenberg says two newer classes of bladder cancer drugs are greatly expanding treatment options for the disease. Promising new drugs have begun to transform the ...
Perseus Proteomics Inc. and Ube Corp. have disclosed antibody-drug conjugates (ADCs) comprising antibodies T004b-PGAP-1 targeting human P-cadherin (CDH3) targeting covalently linked to cytotoxic drug ...
The concept of ADCs was first proposed by Nobel Prize winner Paul Ehrlich in 1913. But it was not until 1975, when hybridoma technology began to be used to produce monoclonal antibodies, that the era ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback